NCT02285465

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of ASP3700 in Healthy Subjects

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Astellas Pharma Europe B.V. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of ascending multiple oral doses of ASP3700 in healthy subjects.

Detailed description

Subjects will be confined in the clinic for 18 days.

Conditions

• Healthy Volunteers
• Pharmacokinetics of ASP3700

Interventions

Type	Name	Description
DRUG	ASP3700	Oral
DRUG	Placebo	Oral

Timeline

• Start date: 2014-11-01
• Primary completion: 2014-11-01
• Completion: 2014-11-01
• First posted: 2014-11-07
• Last updated: 2015-01-12